2.Drug Survival Rates of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
Ji Hyoun KANG ; Dong Jin PARK ; Jeong Won LEE ; Kyung Eun LEE ; Lihui WEN ; Tae Jong KIM ; Yong Wook PARK ; Shin Seok LEE
Journal of Korean Medical Science 2014;29(9):1205-1211
We investigated the compliance of Korean patients using tumor necrosis factor (TNF) inhibitors to treat rheumatoid arthritis (RA) and ankylosing spondylitis (AS), and identified potential predictors associated with treatment discontinuation. The study population comprised 114 RA and 310 AS patients treated with TNF inhibitors at a single tertiary center for at least 1 yr from December 2002 to November 2011. Of the 114 RA patients, 64 (56.1%) discontinued their first TNF inhibitors with a mean duration of 18.1 months. By contrast, 65 of 310 patients (21.0%) with AS discontinued their first TNF inhibitors, with a mean duration of 84 months. Although the survival rate did not differ among the three TNF inhibitors in the AS patients, the etanercept group had a lower discontinuation rate than the infliximab group in the RA patients. In addition, RA patients who received corticosteroids in combination with TNF inhibitors were more likely to discontinue their TNF inhibitors. The independent predictors of drug discontinuation in AS patients were male gender and complete ankylosis on radiographs of the sacroiliac joint. Our results provide further evidence that real-life treatment outcomes of RA and AS patients may be different from those observed in randomized clinical trials.
Adult
;
Aged
;
Antibodies, Monoclonal/therapeutic use
;
Antibodies, Monoclonal, Humanized/therapeutic use
;
Antirheumatic Agents/*therapeutic use
;
Arthritis, Rheumatoid/*drug therapy/mortality
;
Cohort Studies
;
Female
;
Follow-Up Studies
;
Humans
;
Immunoglobulin G/therapeutic use
;
Male
;
Middle Aged
;
Proportional Hazards Models
;
Receptors, Tumor Necrosis Factor/therapeutic use
;
Sex Factors
;
Spondylitis, Ankylosing/*drug therapy/mortality/radiography
;
Tertiary Care Centers
;
Treatment Refusal
;
Tumor Necrosis Factors/*antagonists & inhibitors/metabolism
3.Drug Survival Rates of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
Ji Hyoun KANG ; Dong Jin PARK ; Jeong Won LEE ; Kyung Eun LEE ; Lihui WEN ; Tae Jong KIM ; Yong Wook PARK ; Shin Seok LEE
Journal of Korean Medical Science 2014;29(9):1205-1211
We investigated the compliance of Korean patients using tumor necrosis factor (TNF) inhibitors to treat rheumatoid arthritis (RA) and ankylosing spondylitis (AS), and identified potential predictors associated with treatment discontinuation. The study population comprised 114 RA and 310 AS patients treated with TNF inhibitors at a single tertiary center for at least 1 yr from December 2002 to November 2011. Of the 114 RA patients, 64 (56.1%) discontinued their first TNF inhibitors with a mean duration of 18.1 months. By contrast, 65 of 310 patients (21.0%) with AS discontinued their first TNF inhibitors, with a mean duration of 84 months. Although the survival rate did not differ among the three TNF inhibitors in the AS patients, the etanercept group had a lower discontinuation rate than the infliximab group in the RA patients. In addition, RA patients who received corticosteroids in combination with TNF inhibitors were more likely to discontinue their TNF inhibitors. The independent predictors of drug discontinuation in AS patients were male gender and complete ankylosis on radiographs of the sacroiliac joint. Our results provide further evidence that real-life treatment outcomes of RA and AS patients may be different from those observed in randomized clinical trials.
Adult
;
Aged
;
Antibodies, Monoclonal/therapeutic use
;
Antibodies, Monoclonal, Humanized/therapeutic use
;
Antirheumatic Agents/*therapeutic use
;
Arthritis, Rheumatoid/*drug therapy/mortality
;
Cohort Studies
;
Female
;
Follow-Up Studies
;
Humans
;
Immunoglobulin G/therapeutic use
;
Male
;
Middle Aged
;
Proportional Hazards Models
;
Receptors, Tumor Necrosis Factor/therapeutic use
;
Sex Factors
;
Spondylitis, Ankylosing/*drug therapy/mortality/radiography
;
Tertiary Care Centers
;
Treatment Refusal
;
Tumor Necrosis Factors/*antagonists & inhibitors/metabolism
4.Emerging Drugs in the Treatment of Inflammatory Bowel Disease: Beyond Anti-TNF-alpha.
The Korean Journal of Gastroenterology 2011;58(5):235-244
Understanding of the pathophysiology of inflammatory bowel disease (IBD) is constantly evolving and, recently, a number of biologic agents have been developed. They selectively target specific molecule or pathways and correct the imbalance of the gut immune system. Among them, antibody to tumor necrosis factor (anti-TNF-alpha) is the first developed drugs, and it dramatically improved the IBD management. However, more than one-third of the patients do not respond to the drugs due to antibody formation. To increase treatment efficacy, enormous effort to develop novel anti-cytokines which can be an alternative to anti-TNF-alpha has been made. They are anti CD4+ T cell cytokine including interleukin (IL)-12/23 and IL-17 blockers, selective anti-adhesion molecule known as natalizumab, vedolizumab and alicaforsen, T-cell proliferation inhibitor, anti-inflammatory cytokine, immune stimulator, growth factor, and mitogen-activated protein kinase inhibitor. The efficacy and safety of each drugs are under investigation. Some drugs reported very promising data, however, others showed disappointing and different results. In addition, most of the trials were done in a very small number of patients, and there is no trial comparing to anti-TNF-alpha. The present paper reviews the action mechanism, short or long term efficacy and safety of variable drugs other than anti-TNF-alpha in IBD.
Antibodies, Monoclonal/therapeutic use
;
Cell Migration Inhibition
;
Colony-Stimulating Factors/therapeutic use
;
Cytokines/antagonists & inhibitors
;
Gene Therapy
;
Humans
;
Immunosuppressive Agents/therapeutic use
;
Inflammatory Bowel Diseases/drug therapy/*therapy
;
Intercellular Signaling Peptides and Proteins/therapeutic use
;
Mitogen-Activated Protein Kinases/antagonists & inhibitors
;
Stem Cell Transplantation
;
Tumor Necrosis Factor-alpha/*antagonists & inhibitors/immunology
5.Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor use.
Mie Jin LIM ; Seong Ryul KWON ; Kowoon JOO ; Min Jung SON ; Shin Goo PARK ; Won PARK
The Korean Journal of Internal Medicine 2014;29(6):807-813
BACKGROUND/AIMS: Our aim was to assess whether short-term treatment with soluble tumor necrosis factor (TNF) receptor affects circulating markers of bone metabolism in rheumatoid arthritis (RA) patients. METHODS: Thirty-three active RA patients, treated with oral disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids for > 6 months, were administered etanercept for 12 weeks. Serum levels of bone metabolism markers were compared among patients treated with DMARDs at baseline and after etanercept treatment, normal controls and naive RA patients not previously treated with DMARDs (both age- and gender-matched). RESULTS: Bone-specific alkaline phosphatase (BSALP) and serum c-telopeptide (CTX)-1 levels were lower in RA patients treated with DMARDs than in DMARD-naive RA patients. After 12 weeks of etanercept treatment, serum CTX-1 and sclerostin levels increased. In patients whose DAS28 improved, the sclerostin level increased from 1.67 +/- 2.12 pg/mL at baseline to 2.51 +/- 3.03 pg/mL, which was statistically significant (p = 0.021). Increases in sclerostin levels after etanercept treatment were positively correlated with those of serum CTX-1 (r = 0.775), as were those of BSALP (r = 0.755). CONCLUSIONS: RA patients treated with DMARDs showed depressed bone metabolism compared to naive RA patients. Increases in serum CTX-1 and sclerostin levels after short-term etanercept treatment suggest reconstitution of bone metabolism homeostasis.
Adult
;
Alkaline Phosphatase/blood
;
Arthritis, Rheumatoid/blood/diagnosis/*drug therapy
;
Biological Markers/blood
;
Bone Morphogenetic Proteins/blood
;
Bone Remodeling/*drug effects
;
Collagen Type I/blood
;
Female
;
Genetic Markers
;
Homeostasis
;
Humans
;
Immunoglobulin G/*administration & dosage
;
Immunosuppressive Agents/*administration & dosage
;
Inflammation Mediators/blood
;
Male
;
Middle Aged
;
Peptides/blood
;
Receptors, Tumor Necrosis Factor/*administration & dosage
;
Time Factors
;
Treatment Outcome
;
Tumor Necrosis Factor-alpha/antagonists & inhibitors
6.Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-alpha inhibitor.
Keun Bum CHUNG ; Eun Young LEE ; Jong Pil IM ; Sung Koo HAN ; Jae Joon YIM
The Korean Journal of Internal Medicine 2013;28(2):174-179
BACKGROUND/AIMS: Individuals being treated with tumor necrosis factor (TNF)-alpha inhibitors are at increased risk of developing tuberculosis (TB). We determined the clinical characteristics and treatment response of patients who developed TB after using TNF-alpha inhibitors. METHODS: Patients with TB detected within 12 months of the initiation of TNF-alpha inhibitor treatment were included, if seen from January 1, 2000 to August 31, 2011. We retrospectively reviewed the clinical records, results of bacteriological examinations, and radiographs of the included patients and the response to anti-TB treatment. RESULTS: We indentified seven cases of TB in 457 patients treated with TNF-alpha inhibitors during the study period. TB developed a median of 123 days (range, 48 to 331) after the first dose of TNF-alpha inhibitor. Pulmonary TB, including TB pleuritis, was diagnosed in three patients and extrapulmonary TB in four. Favorable treatment outcomes were achieved in six of seven patients. CONCLUSIONS: Among the TNF-alpha inhibitor users who contracted TB, extrapulmonary sites were common and the treatment response was satisfactory.
Adult
;
Aged
;
Antitubercular Agents/therapeutic use
;
Female
;
Humans
;
*Immunocompromised Host
;
Immunosuppressive Agents/*adverse effects
;
Interferon-gamma Release Tests
;
Male
;
Middle Aged
;
Retrospective Studies
;
Risk Factors
;
Time Factors
;
Treatment Outcome
;
Tuberculin Test
;
Tuberculosis/diagnosis/drug therapy/*immunology/microbiology
;
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
7.Drug-Induced Liver Injury: Pattern Recognition and Future Directions.
Tanvir HAQUE ; Eizaburo SASATOMI ; Paul H HAYASHI
Gut and Liver 2016;10(1):27-36
Drug-induced liver injury (DILI) remains a significant clinical challenge and is the leading cause of acute liver failure in most countries. An aging population that uses more medications, a constant influx of newly developed drugs and a growing risk from unfamiliar herbal and dietary supplements will make DILI an increasing part of clinical practice. Currently, the most effective strategy for disease management is rapid identification, withholding the inciting agents, supportive care and having a firm understanding of the expected natural history. There are resources available to aid the clinician, including a new online "textbook" as well as causality assessment tools, but a heightened awareness of risk and the disease's varying phenotypes and good history-taking remain cornerstones to diagnosis. Looking ahead, growing registries of cases, pharmacoepidemiology studies and translational research into the mechanisms of injury may produce better diagnostic tools, markers for risk and disease, and prevention and therapeutics.
Age Factors
;
Anti-Infective Agents/adverse effects
;
Anti-Inflammatory Agents, Non-Steroidal/adverse effects
;
Anticonvulsants/adverse effects
;
Biopsy
;
Dietary Supplements/adverse effects
;
Drug-Induced Liver Injury/*diagnosis/epidemiology
;
Drugs, Chinese Herbal/adverse effects
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects
;
Incidence
;
Liver/pathology
;
Liver Function Tests
;
Risk Factors
;
Tumor Necrosis Factor-alpha/antagonists & inhibitors
8.Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent.
Bon San KOO ; Seokchan HONG ; You Jae KIM ; Yong Gil KIM ; Chang Keun LEE ; Bin YOO
The Korean Journal of Internal Medicine 2015;30(1):104-109
BACKGROUND/AIMS: To evaluate the impact on mortality of anti-tumor necrosis factor (anti-TNF) treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). METHODS: We retrospectively reviewed the medical records of 100 RA-ILD patients who visited our tertiary care medical center between 2004 and 2011, identified those treated with an anti-TNF agent, divided patients into non-survivor and survivor groups and evaluated their clinical characteristics and causes of death. RESULTS: A total of 24 RA-ILD patients received anti-TNF therapy, of whom six died (25%). Mean age at initiation of anti-TNF therapy was significantly higher in the nonsurvivor versus survivor group (76 years [range, 66 to 85] vs. 64 years [range, 50 to 81], respectively; p = 0.043). The mean duration of anti-TNF treatment in the non-survivor group was shorter (7 months [range, 2 to 14] vs. 23 months [range, 2 to 58], respectively; p = 0.030). The duration of anti-TNF therapy in all nonsurviving patients was < 12 months. Pulmonary function test results at ILD diagnosis, and cumulative doses of disease-modifying drugs and steroids, did not differ between groups. Five of the six deaths (83%) were related to lung disease, including two diffuse alveolar hemorrhages, two cases of acute exacerbation of ILD, and one of pneumonia. The sixth patient died of septic shock following septic arthritis of the knee. CONCLUSIONS: Lung complications can occur within months of initial anti-TNF treatment in older RA-ILD patients; therefore, anti-TNF therapy should be used with caution in these patients.
Adult
;
Aged
;
Aged, 80 and over
;
Antirheumatic Agents/adverse effects/*therapeutic use
;
Arthritis, Rheumatoid/complications/diagnosis/*drug therapy/immunology/mortality
;
Female
;
Humans
;
Lung Diseases, Interstitial/diagnosis/etiology/*mortality
;
Male
;
Middle Aged
;
Republic of Korea
;
Retrospective Studies
;
Risk Assessment
;
Risk Factors
;
Tertiary Care Centers
;
Time Factors
;
Treatment Outcome
;
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
9.Chronic ethanol feeding impairs AMPK and MEF2 expression and is associated with GLUT4 decrease in rat myocardium.
LiYong CHEN ; FuRong WANG ; XiangLan SUN ; Jing ZHOU ; Ling GAO ; YuLian JIAO ; XiaoLei HOU ; ChengYong QIN ; JiaJun ZHAO
Experimental & Molecular Medicine 2010;42(3):205-215
Chronic and heavy alcohol consumption is one of the causes of heart diseases. However, the effects of ethanol on insulin sensitivity in myocardium has been unclear. To investigate the effects of ethanol on the expression of AMP-activated protein kinase (AMPK), myocyte enhancer factor 2 (MEF2) and glucose transporter 4 (GLUT4), all of which are involved in the regulation of insulin sensitivity, in the myocardium, we performed three parts of experiments in vivo and in vitro. I: Rats were injected with 5-amino-4-imidazolecarboxamide ribonucleotide (AICAR, 0.8 mg.kg(-1)) for 2 h. II: Rats received different dose (0.5, 2.5 or 5 g.kg(-1).d(-1)) of ethanol for 22-week. III: Primary neonatal rat cardiomyocytes were isolated and treated with or without 100 mM ethanol or 1 mM AICAR for 4 h. The cardiac protein and mRNA expression of AMPKalpha subunits, MEF2 and GLUT4 were observed by western-blotting and RT-PCR, respectively. Serum TNFalpha levels were assessed by ELISA. The results showed chronic ethanol exposure induced insulin resistance. Ethanol decreased the mRNA levels of AMPKalpha1 and alpha2, the protein levels of total- and phospho-AMPKalpha in cardiomyocytes. Similarly, ethanol showed inhibitory effects on both the mRNA and protein levels of MEF2A and 2D, and GLUT4 in a dose-response-like fashion. Correlation analysis implied an association between phospho-AMPKalpha and MEF2A or MEF2D, and between the levels of MEF2 protein and GLUT4 transcription. In addition, ethanol elevated serum TNFalpha level. Taken together, chronic ethanol exposure decreases the expression of AMPKalpha and MEF2, and is associated with GLUT4 decline in rat myocardium.
AMP-Activated Protein Kinases/genetics/*metabolism
;
Aminoimidazole Carboxamide/analogs & derivatives/pharmacology
;
Animals
;
Enzyme Activation/drug effects
;
Ethanol/*administration & dosage/*pharmacology
;
Feeding Behavior/*drug effects
;
Gene Expression Regulation/drug effects
;
Glucose Transporter Type 4/genetics/*metabolism
;
Insulin/pharmacology
;
Insulin Resistance
;
Male
;
Myocardium/*enzymology
;
Myogenic Regulatory Factors/antagonists & inhibitors/genetics/*metabolism
;
Protein Isoforms/antagonists & inhibitors/genetics/metabolism
;
RNA, Messenger/genetics/metabolism
;
Rats
;
Rats, Wistar
;
Ribonucleotides/pharmacology
;
Time Factors
;
Tumor Necrosis Factor-alpha/blood
10.The use of biological agents in the treatment of rheumatoid arthritis.
Peng Thim FAN ; Keng Hong LEONG
Annals of the Academy of Medicine, Singapore 2007;36(2):128-134
Rheumatoid arthritis is a common and potentially devastating condition which did not have good treatment options until recently. Pharmacological treatment should not just comprise antiinflammatory agents and corticosteroids. The current therapeutic approach is to start a disease modifying agent early in the illness to prevent eventual joint damage. Older disease modifying anti-rheumatic drugs (DMARDs) include methotrexate, sulphasalazine and hydroxychloroquine. Newer ones such as leflunomide and cyclosporine are also used. A recent advance in the management of rheumatoid arthritis is the use of biological agents which block certain key molecules involved in the pathogenesis of the illness. They include tumour necrosis factor (TNF)- blocking agents such as infliximab, etanercept and adalimumab, the anti-CD 20 agent rituximab and CTLA-4 Ig abatacept. Other agents which are in development include anti-IL6 tocilizumab, anti-CD22 and anti-lymphostat B. In this review, the efficacy and side effects of these agents, their impact on current clinical practice and future trends are discussed.
Abatacept
;
Antibodies, Monoclonal
;
therapeutic use
;
Antibodies, Monoclonal, Humanized
;
Antirheumatic Agents
;
therapeutic use
;
Arthritis, Rheumatoid
;
immunology
;
therapy
;
Drug Therapy, Combination
;
Humans
;
Immunoconjugates
;
therapeutic use
;
Immunologic Factors
;
adverse effects
;
therapeutic use
;
Immunosuppressive Agents
;
therapeutic use
;
Methotrexate
;
therapeutic use
;
Remission Induction
;
Tumor Necrosis Factor-alpha
;
antagonists & inhibitors